RxDoctor Payments Data

Allison Ringle, NP

Family · Wakeman, OHNPI 1194386169

Payments from drug & device makers

$423in general payments, 2019–2025

Across 12 payments — averaging $35.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$140
  • Johnson & Johnson$125
  • Lilly USA, LLC$32
  • Novo Nordisk$28
  • Biohaven Pharmaceuticals, Inc.$24
  • Amarin Pharma, Inc.$19
  • plus $55 from 4 others

What the payments were for

  • Food & beverage$423100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$423 in reported general payments places this provider in the 55th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$15,521
Medicare patients
83
Services billed
188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$26,488
EliquisApixaban11$7,584
Atorvastatin Calcium116$1,026
Albuterol Sulfate HfaAlbuterol Sulfate26$885
Pregabalin15$413
Famotidine36$412
Losartan Potassium32$408
Carvedilol41$388
Oxybutynin Chloride ErOxybutynin Chloride33$368
Levothyroxine Sodium54$331
Lisinopril39$313
Metformin Hcl34$310
Fluticasone Propionate15$277
Levocetirizine Dihydrochloride13$266
Pantoprazole Sodium23$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$28$26,48818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 6,812 family providers in Ohio.

Other family in Wakeman

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →